Preveceutical Medical IncOTCQB:PRVCFView on Canadian Exchange
- LAST PRICE0.0107
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0107
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PRVCF |
|---|---|---|
| 09:32 ET | 3150 | 0.0113 |
| 10:40 ET | 1130 | 0.0158 |
| 12:24 ET | 6400 | 0.0143 |
| 02:34 ET | 1250 | 0.01455 |
| 03:50 ET | 100000 | 0.0107 |
Yesterday
Nov 15, 2024
PreveCeutical Announces Closing of BioGene Therapeutics Transaction, from 2:50PM ET on Friday Nov 15, 2024 by Dow Jones
2:50PM ET on Friday Nov 15, 2024 by Dow Jones
Nov 13, 2024
PreveCeutical's Subsidiary, BioGene Therapeutics, Appoints President, from 7:02AM ET on Wednesday Nov 13, 2024 by Dow Jones
7:02AM ET on Wednesday Nov 13, 2024 by Dow Jones
Oct 30, 2024
PreveCeutical Launches Strategic Partnership with BioGene Therapeutics, from 6:32AM ET on Wednesday Oct 30, 2024 by Dow Jones
6:32AM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Preveceutical Medical Inc | 10.8M | --- | --- |
Company Information
PreveCeutical Medical Inc. is a Canada-based health sciences company. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Company’s pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, BSV Peptide Program and Dual Gene Therapy. Its Cannabinoid Sol-Gel is cannabinoid-based nose-to-brain delivery system that provides relief to a range of indications from pain, inflammation, seizures, and neurological disorders. Its BSV peptide program targets cancer progression. Its Non-Addictive Analgesic is an engineering non-addictive analgesic peptide for pain management. Its Dual Gene Therapy targets type 2 diabetes and obesity. The Company’s subsidiary, PreveCeutical (Australia) Pty Ltd., manages its research programs.
Contact Information
- Headquarters
- 5428 Marine DriveWEST VANCOUVER, BC, Canada V7W 2R2
- Phone
- 604-416-7777
- Fax
- 778-945-6290
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $10.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 541.7M |
Preveceutical Medical Inc does not pay a dividend. | |
Beta | 1.00 |
EPS | $0.00 |
Book Value | $-0.01 |
P/E Ratio | --- |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
